Risk of second primary malignancies in a population-based study of adult patients with essential thrombocythemia

Rajesh Shrestha, Smith Giri, Ranjan Pathak, Vijaya R Bhatt

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

AIM: To determine the risk of second primary malignancy (SPM) and survival of patients with essential thrombocythemia (ET). METHODS: We identified all patients with ET diagnosed during 2001 to 2011 from the Surveillance, Epidemiology and End Results (SEER) 18 database. Actuarial and relative survival methods were used to calculate the survival statistics. We utilized the SEER 13 database to calculate SPM. We used multiple primary standardized incidence ratio (SIR) session of the SEER∗Stat software (version 8.1.5) to calculate SIR and excess risk of SPM for ET patients. RESULTS: Age standardized five-year cause-specific survival was greater for patients < 50 years vs those ≥ 50 years (99.4% vs 93.5%, P < 0.01). Five-year cause-specific survival was lower for men vs women (70.2% vs 79.7%). A total of 201 patients (2.46%) developed SPM at a median age of 75 years. SPMs occurred at an observed/expected (O/E) ratio of 1.26 (95%CI: 1.09-1.45, P = 0.002) with an absolute excess risk (AER) of 37.44 per 10000 population. A significantly higher risk was noted for leukemia (O/E 3.78; 95%CI: 2.20-6.05, P < 0.001; AER 11.28/10000). CONCLUSION: ET patients have an excellent cause-specific five-year survival but are at an increased risk of SPM, particularly leukemia, which may contribute to excess deaths.

Original languageEnglish (US)
Pages (from-to)324-330
Number of pages7
JournalWorld Journal of Clinical Oncology
Volume7
Issue number4
DOIs
StatePublished - Aug 10 2016

Fingerprint

Essential Thrombocythemia
Second Primary Neoplasms
Survival
Population
Leukemia
Epidemiology
Databases
Incidence
Software
Odds Ratio

Keywords

  • Essential thrombocythemia
  • Second primary malignancy
  • Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Risk of second primary malignancies in a population-based study of adult patients with essential thrombocythemia. / Shrestha, Rajesh; Giri, Smith; Pathak, Ranjan; Bhatt, Vijaya R.

In: World Journal of Clinical Oncology, Vol. 7, No. 4, 10.08.2016, p. 324-330.

Research output: Contribution to journalArticle

@article{5f49b830622446bb8371cacf5eee04a1,
title = "Risk of second primary malignancies in a population-based study of adult patients with essential thrombocythemia",
abstract = "AIM: To determine the risk of second primary malignancy (SPM) and survival of patients with essential thrombocythemia (ET). METHODS: We identified all patients with ET diagnosed during 2001 to 2011 from the Surveillance, Epidemiology and End Results (SEER) 18 database. Actuarial and relative survival methods were used to calculate the survival statistics. We utilized the SEER 13 database to calculate SPM. We used multiple primary standardized incidence ratio (SIR) session of the SEER∗Stat software (version 8.1.5) to calculate SIR and excess risk of SPM for ET patients. RESULTS: Age standardized five-year cause-specific survival was greater for patients < 50 years vs those ≥ 50 years (99.4{\%} vs 93.5{\%}, P < 0.01). Five-year cause-specific survival was lower for men vs women (70.2{\%} vs 79.7{\%}). A total of 201 patients (2.46{\%}) developed SPM at a median age of 75 years. SPMs occurred at an observed/expected (O/E) ratio of 1.26 (95{\%}CI: 1.09-1.45, P = 0.002) with an absolute excess risk (AER) of 37.44 per 10000 population. A significantly higher risk was noted for leukemia (O/E 3.78; 95{\%}CI: 2.20-6.05, P < 0.001; AER 11.28/10000). CONCLUSION: ET patients have an excellent cause-specific five-year survival but are at an increased risk of SPM, particularly leukemia, which may contribute to excess deaths.",
keywords = "Essential thrombocythemia, Second primary malignancy, Survival",
author = "Rajesh Shrestha and Smith Giri and Ranjan Pathak and Bhatt, {Vijaya R}",
year = "2016",
month = "8",
day = "10",
doi = "10.5306/wjco.v7.i4.324",
language = "English (US)",
volume = "7",
pages = "324--330",
journal = "World Journal of Clinical Oncology",
issn = "2218-4333",
publisher = "Baishideng Publishing Group",
number = "4",

}

TY - JOUR

T1 - Risk of second primary malignancies in a population-based study of adult patients with essential thrombocythemia

AU - Shrestha, Rajesh

AU - Giri, Smith

AU - Pathak, Ranjan

AU - Bhatt, Vijaya R

PY - 2016/8/10

Y1 - 2016/8/10

N2 - AIM: To determine the risk of second primary malignancy (SPM) and survival of patients with essential thrombocythemia (ET). METHODS: We identified all patients with ET diagnosed during 2001 to 2011 from the Surveillance, Epidemiology and End Results (SEER) 18 database. Actuarial and relative survival methods were used to calculate the survival statistics. We utilized the SEER 13 database to calculate SPM. We used multiple primary standardized incidence ratio (SIR) session of the SEER∗Stat software (version 8.1.5) to calculate SIR and excess risk of SPM for ET patients. RESULTS: Age standardized five-year cause-specific survival was greater for patients < 50 years vs those ≥ 50 years (99.4% vs 93.5%, P < 0.01). Five-year cause-specific survival was lower for men vs women (70.2% vs 79.7%). A total of 201 patients (2.46%) developed SPM at a median age of 75 years. SPMs occurred at an observed/expected (O/E) ratio of 1.26 (95%CI: 1.09-1.45, P = 0.002) with an absolute excess risk (AER) of 37.44 per 10000 population. A significantly higher risk was noted for leukemia (O/E 3.78; 95%CI: 2.20-6.05, P < 0.001; AER 11.28/10000). CONCLUSION: ET patients have an excellent cause-specific five-year survival but are at an increased risk of SPM, particularly leukemia, which may contribute to excess deaths.

AB - AIM: To determine the risk of second primary malignancy (SPM) and survival of patients with essential thrombocythemia (ET). METHODS: We identified all patients with ET diagnosed during 2001 to 2011 from the Surveillance, Epidemiology and End Results (SEER) 18 database. Actuarial and relative survival methods were used to calculate the survival statistics. We utilized the SEER 13 database to calculate SPM. We used multiple primary standardized incidence ratio (SIR) session of the SEER∗Stat software (version 8.1.5) to calculate SIR and excess risk of SPM for ET patients. RESULTS: Age standardized five-year cause-specific survival was greater for patients < 50 years vs those ≥ 50 years (99.4% vs 93.5%, P < 0.01). Five-year cause-specific survival was lower for men vs women (70.2% vs 79.7%). A total of 201 patients (2.46%) developed SPM at a median age of 75 years. SPMs occurred at an observed/expected (O/E) ratio of 1.26 (95%CI: 1.09-1.45, P = 0.002) with an absolute excess risk (AER) of 37.44 per 10000 population. A significantly higher risk was noted for leukemia (O/E 3.78; 95%CI: 2.20-6.05, P < 0.001; AER 11.28/10000). CONCLUSION: ET patients have an excellent cause-specific five-year survival but are at an increased risk of SPM, particularly leukemia, which may contribute to excess deaths.

KW - Essential thrombocythemia

KW - Second primary malignancy

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84979895561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979895561&partnerID=8YFLogxK

U2 - 10.5306/wjco.v7.i4.324

DO - 10.5306/wjco.v7.i4.324

M3 - Article

VL - 7

SP - 324

EP - 330

JO - World Journal of Clinical Oncology

JF - World Journal of Clinical Oncology

SN - 2218-4333

IS - 4

ER -